AMDX2011P

Small molecule

AAmydis Inc.

AMDX2011P is one of 10 small molecule programs targeting Neurodegenerative Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

3 2

Robitussin

Aricept

1 4

Namenda

AbbVie

Preclinical

1 5

THK-5351

JJae Seung Kim

Phase 2

1 6

Intropin

Pfizer

Preclinical

—7

MC225

UUniversity Medical Center Groningen

Phase 2

1 8

Citicoline

UUniversity of Texas Southwestern Medical Center

SNP318

1 10

AMDX2011P

AAmydis Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurodegenerative Disease1 trial

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

Completed·AAmydis Inc.·Phase 1/2·NCT05542576·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMDX2011P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMDX2011P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMDX2011P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amydis Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAmydis Inc.

AMDX2011P

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurodegenerative Disease1 trial

References

Drug Info

Quick Facts

Related News